Connect with us

Technology

Frost & Sullivan Released Report: “BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies”

Published

on

SHANGHAI, Sept. 2, 2024 /PRNewswire/ — Frost & Sullivan released a report, titled “BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies”. The report explores a global CDMO leading the “The Fourth Revolutionary Wave of Biologics Manufacturing” and pioneering the next generation of CDMO models.

The global biomanufacturing capacity gap and budget constraints have ignited the “The Fourth Revolutionary Wave of Biologics Manufacturing”, with production sites expanding towards million-liter scales. In this context, Contract Development and Manufacturing Organizations (CDMOs) have become key players in global biomanufacturing. In 2023, BiBo Pharma, founded in Boston, USA, introduced a new generation of ultra-large production platforms, marking a new era in biomanufacturing. BiBo Pharma is breaking capacity barriers and reducing antibody drug production costs from the international average of hundreds of dollars to just $10 per gram, offering disruptive solutions to global biopharmaceutical companies.

Part I: BiBo Pharma 1.0 : Reflecting on the Past – Originating in Boston, USA, and Navigating through the Global CDMO development Journey

In the increasingly competitive CDMO industry, BiBo Pharma continues to advance. This success is due not only to their precise grasp of market opportunities but also to their breakthroughs in core biopharmaceutical industrialization technologies. Sailing from Boston, BiBo Pharma has been committed to the commercial production of biologics since its inception. The company independently designed and manufactured the ultra-large stainless steel bioreactors and pioneers a new generation of production models. In 2023, BiBo Pharma successfully completed the construction of a 30,000L single-tank ultra-large-production line, and in March 2024, it successfully commenced operations.

BiBo Pharma developed a comprehensive technology platform for microbial fermentation, mammalian cell culture, gene therapy, and antibody-drug conjugates (ADC). This platform offers one-stop services from DNA to IND/BLA and large-scale commercial production. To date, BiBo Pharma has offered CDMO services for more than 130 large molecule projects. Their operations adhere to international quality and management standards, solidifying BiBo Pharma’s position on the global CDMO stage after a decade of dedicated effort, and pioneering the next generation of CDMO models.

Part II: BiBo Pharma 2.0: Current Focus – Upgrading Strategies and Expanding Capabilities

//30,000L Capacity Advantage and Global First Delivery Advantage as an Industry Pioneer//

Major global CDMOs are expanding their large-scale commercial production capacities by focusing on the construction of large-scale stainless steel bioreactors. The future direction involves advancing from the current 15,000L reactors to fourth-generation ultra-large-scale production technologies.

BiBo Pharma is the first and only CDMO to deliver a new generation of ultra-large stainless steel bioreactors with a maximum working volume of 30,000L per tank. This is an engineering scale-up of over 2.5 times compared to the current 15,000L (total volume) standard in large-scale biopharmaceutical production. BiBo Pharma leverages economies of scale and cost-sharing to offer a potential solution to reduce costs on the basis of ensuring independently designed core equipment and a controllable supply chain.

PanFlex®-Engineering: Breaking Through the “Quality-Cost-Efficiency” Triangle  

The conventional factory construction process adopts an engineering design model that proceeds from the top level down to the lower levels. PanFlex®-Engineering employs a “Process is King” strategy, using standardized units to reverse-engineer a complete factory. As a result, PanFlex®-Engineering system transcends the impossible triangle of “quality-cost-efficiency.” Remarkably, it took less than 18 months to deliver a 30,000L ultra-large production platform, roughly half the time and cost of similar projects worldwide. In addition, the 30,000L platform passed quality audits from the U.S., EU, and Chinese clients. Leveraging its PanFlex®-Operation system, Bibo Pharma achieved a “Right on First Time” in March 2024 when the platform was put into operation with a 100% success rate in subsequent production.

Grand-CHO Platform: A “Three-in-one” Approach to Innovation

A “Three-in-One” approach to innovation——Grand-CHO Platform involves advances in cell line development, process research, and production technology for ultra-large-scale platforms.

Grand-CHO platform improves cell line expression and stability, optimizes commercial production processes of different scales, and offers other benefits. The second-generation Epic-CHO cell line achieves a high expression level of 10 g/L at the mini-pool stage and offers more than double the stability of leading international cell lines, laying a solid foundation for large-scale production.

Grand-CHO technology enables high-density and large-scale cell storage, while seamlessly integrating a 3,000L N-1 perfusion process and a 30,000L intensified Fed-batch production process. Compared to traditional methods, Grand-CHO technology reduces production cycle time by 30%, doubles the yield per fermentation volume, and cuts restart time for 30,000L projects from 60 days to 30 days. Grand-CHO technology, integrated with the 30,000L ultra-large-scale production line, is fundamentally transforming the overall production efficiency of biopharmaceuticals.  

Pulse Continuous Manufacturing (PCM)

The combination of BiBo Pharma’s PanFlex®-Engineering and Grand-CHO technology has led to a groundbreaking production model — Pulse Continuous Manufacturing (PCM). PCM releases a single high-volume batch upstream, such as 60,000 liters per pulse (60kL/P). It then processes multiple downstream batches continuously based on each unit’s operation time. PCM significantly improves production efficiency, boosting overall line efficiency by 50% to 300%. PCM’s success is driven by the interconnected equipment enabled by PanFlex®-Engineering. Additionally, BiBo’s P03 plant has implemented an automated process control system (PAS) that enables full digital integration across the facility, making the execution of the PCM model more efficient and seamless. 

Technology Integration Drives Reduction of Antibody Drug Production Cost to $10 per Gram

The primary initiative to solve the constraints of production costs, is the international breakthrough of the first-ever 30,000L single-tank ultra-large-scale production line. Integrating PanFlex®-Engineering, Grand-CHO technology, and a pulse continuous production mode, BiBo Pharma reduce antibody drug production cost from hundreds of dollars to $10 per gram.

An Engineering and Technical Service Provider

BiBo Pharma has launched the pioneering “Blue Whale Program,” a financial risk-free manufacturing solution powered by the PanFlex® system. This program offers tailored production line construction services to global clients, which reduces the construction costs and timelines by 50%. This allows clients to postpone capital expenditure decisions from Phase I/II to Phase III of clinical trials, giving them more time to make informed investment choices. Additionally, the program provides a risk reduction feature: fees paid by clients are refundable regardless of whether the product succeeds in the market. This effectively offers additional insurance for commercialization and mitigates risks in the R&D and production phases.

Part III: BiBo Pharma 3.0: Shaping the Future – Establishing Comprehensive Technology Industry Advantages and Leading the Next Chapter

BiBo Pharma establishes an intensive production model, which underpins the company a diversified, full-technology platform offering one-stop CDMO services. With its Boston R&D center and global production capabilities, BiBo Pharma delivers high-quality services adhering to international standards. BiBo Pharma utilizes its unparalleled industry advantages to empower the global biopharmaceutical companies by reshaping the cost structure of biologics.

Additionally, the “Blue Whale Program” expands BiBo Pharma’s established engineering solutions, reaching more clients with commercial production needs. Frost & Sullivan expects that these capabilities and advantages will position BiBo Pharma as the best solution for global pharmaceutical companies in the future.

To read the full content, go here: https://www.frost.com/news/press-releases/bibo-pharma-a-global-cdmo-leading-in-advanced-biopharmaceutical-manufacturing-technologies/

Media Contact
Contact: Qian Li
Company Name: Frost & Sullivan
Website: http://www.frostchina.com
Email: qian.li@frostchina.com 

View original content:https://www.prnewswire.com/apac/news-releases/frost–sullivan-released-report-bibo-pharma-a-global-cdmo-leading-in-advanced-biopharmaceutical-manufacturing-technologies-302235863.html

SOURCE Frost & Sullivan

Continue Reading

Technology

Canton Fair Buyers Alliance Launched as the 140th Edition Opens

Published

on

By

GUANGZHOU, China, Oct. 17, 2026 /PRNewswire/ — On October 15, the Canton Fair Buyers Alliance was officially launched at the Canton Fair Complex, marking a significant milestone as the fair celebrates the 70th anniversary of its founding.

More than 140 overseas buyers attended the launch ceremony, highlighting the fair’s enduring role as a bridge connecting global commerce with China’s export sector.

Speaking at the ceremony, Luís Vilariça, CEO of Joinco, Import & Export, Ltd., discussed his company’s long-standing relationship with the Canton Fair. Drawing on years of participation, he reflected on the growth opportunities created through cooperation with Chinese suppliers and highlighted the fair’s role in supporting international business development and global trade exchanges.

The ceremony also featured a joint declaration by alliance members. Representatives from five member companies read the statement in their respective native languages, underscoring the international character of the new organization. Additional members sent video congratulatory messages, joining the celebration and witnessing the official launch of the alliance.

The Canton Fair Buyers Alliance represents one of the fair’s key service innovations. Designed primarily for Fortune Global 500 companies, buyers from the world’s top 250 retailers and leading sourcing enterprises across a diverse range of markets, the alliance aims to offer members a platform for information sharing and resource coordination. The first cohort of alliance members includes 58 companies from 32 countries and regions across 5 continents. Through the alliance, members will gain access to a range of priority benefits spanning four major areas: services, events, resources and information.

 For more convenient attendance, please click here for pre-registration:

https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

View original content to download multimedia:https://www.prnewswire.com/news-releases/canton-fair-buyers-alliance-launched-as-the-140th-edition-opens-302911896.html

SOURCE Canton Fair

Continue Reading

Technology

Bioethanol from human hair – Indian start-up’s solution to rising prices of grains and sugar

Published

on

By

GUJARAT, India, Oct. 17, 2026 /PRNewswire/ — In what could be called the beginning of the 5G (fifth-generation) of bioethanol or non-cellulosic bioethanol or non-sugar-based biofuels, an Indian start-up, Techofest Global, based out of Gujarat, has developed its own, indigenous, and patented technology for the production of bioethanol from waste human hair. Such processes would significantly reduce the employment of sugars, grains, and agricultural residues, which form the classical first- and second-generation bioethanol feedstocks. As a result, the rising fuel-vs.-food/fodder debate is anticipated to reduce, and instead, ethanol produced from municipal/industrial waste, after trials, can supplement the current supply being used as blends with presently retailed fossil fuels (E20, E27, etc.). 

As stated by Dr. Ravi, the founder-CEO of Techofest Global, the strategic priority and the USP of the start-up is industrial symbiosis, which, typically, involves an ecosystem of up-cycling/valorising the effluents of an industry, thereby creating a value-chain for residues often lacking an end-of-life. With more than three decades of experience in designing customized nuclear fusion reactors for international programmes, such as ITER, JET/UKAEA and SST-1, Dr. Ravi, a seasoned mechanical engineer, spearheads the start-up’s patented technologies’ scale-up and commercialization.

Two biochemical engineers, Dr. Navnit – the former CTO, and Dr. Kabilan – the former CEO of Biomakerz, Chennai, are the brains behind the current technology/process portfolio of the joint-venture between Techofest Global and Biomakerz. They have been working on biorefineries’ process intensification for more than a decade. “Having foreseen the fuel-vs-fodder/food competition as early as the year 2015, we began developing techno-economically feasible and viable in-vitro metabolically-engineered bioprocesses for scaling-up ethanol production from municipal waste streams between 2019–2021”, says Navnit. After developing operational technologies for international biofuel organizations, serving process engineer roles with certain biorefineries-related OMC R&D’s of India, Dr. Navnit, presently works for a premier academic institution.

An on-going fermentation trial at the Techofest Global-Biomakerz JV’s R&D facility

Techofest Global has developed and tested, in its R&D JV’s pilot-facility of ~100-L, 3 innovative and cost-effective technologies, such as 5G ethanol production using human hair, used cooking oil (UCO), and enriched bio-methane production from disposed sanitary napkins.

“With massive CapEx and OpEx, 2G ethanol technology is facing a major commercialization bottleneck, owing to competition with food/livestock fodder, requirement of a cost-intensive pre-treatment procedure, and the requirement of cellulolytic cocktails, which have a poor recycle efficiency. The proprietary 5G SAFE process developed for the start-up circumvents the mentioned constraints, and instead, utilizes a single-stage saccharification followed by fermentation, and records over 85–90% biocatalyst recovery. Likewise, the proprietary SIM process for bio-methane production, exclusively developed for the start-up, is 2x faster with improved intermittent feeding cycles and continuous gas harvest”, says Navnit.

“With on-going pre-commercialization trials, the proprietary ethanol and bio-methane processes of ours are soon being commercialized”, says Ms. Bhumika, the co-founder and the corporate advisor of the start-up. Furthermore, Mr. Ronak pilots the organization’s global market entry and commercialization frontier.

Techofest Global’s veteran Principal Technology Advisors include: Dr VS Tripathi, former Joint Director, DRDE Gwalior, Dr B S Munjal, former Director, Structures and Thermal group, SAC/ISRO, Academician and Advisor CIKS-Dharohar, GTU, and Dr AV Santhanababu, former Scientist at Satish Dhawan Space Centre. With on-going R&D activities, Dr. Munjal says, “the start-up is striving to provide a unique solution along the lines of the Atmanirbhar and Viksit Bharat Vision 2047”.

Media Contact: www.techofestglobal.com; e-mail: info@techofestglobal.com; contact person: The PR team of Techofest Global.

Photo: https://mmx.prnewswire.com/media/MS2015507/Picture1.jpg?id=OA3024965&token=5vT9XuZXAG0yamsZlRrsBAiUapaplm73wYH8NIfU0xCtOlj76dueXcTw2Eb-3w

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/bioethanol-from-human-hair–indian-start-ups-solution-to-rising-prices-of-grains-and-sugar-302911813.html

Continue Reading

Technology

As AI Speeds Up Marketing, Louisville’s RedTag Bets on Strategy

Published

on

By

Independent agency unveils new brand and website, and co-hosts Louisville’s PROOF AI Workshop

LOUISVILLE, Ky., Oct. 17, 2026 /PRNewswire/ — RedTag, an independent Louisville-based marketing agency, this month unveiled new positioning, marking its evolution from a digital performance agency into a strategy-first marketing partner. The move comes as AI makes execution faster than ever, and RedTag is betting that strategy, not speed, is what will set businesses apart. Clients can now choose from outcome-based programs that best fit their marketing needs. 

“Clients don’t come to us needing more tactics. They come to us needing a path,” said Russ Renbarger, founder and CEO of RedTag. “Our new brand says out loud what our work has shown for years: We start with strategy and build everything on that foundation.”

RedTag built its reputation on high-performing paid digital campaigns. Over the years, the agency expanded into strategy, creative, video production and website development, giving clients one partner for the full scope of their marketing. Most recently, a team of automation specialists has integrated AI across the agency to speed up production and analysis, guided by an internal AI policy that keeps people accountable for quality. The time AI saves goes back into strategy: knowing what to say, who to say it to and why.

“Our best client relationships have always been partnerships, where we’re in the room when the big decisions get made,” said Alison Conway, chief client officer at RedTag. “This evolution is about bringing that strategic partnership to every client.”

On Oct. 14, RedTag co-hosted the PROOF AI Workshop with Slingshot, Vsimple and Advanced Business Solutions. The hands-on event gave Louisville business leaders practical experience applying AI to their own work. RedTag led the event’s AI in Marketing and Branding track, with four sessions ranging from AI search optimization to a playbook for adopting AI across an organization.

“AI can produce hundreds of ads in an afternoon, but it can’t tell you which one your brand actually needs and why,” Renbarger said. “The faster the tools get, the more valuable human-led strategy becomes.”

RedTag was named the agency of record for the Commonwealth of Kentucky in 2025. Its client list includes PGA of America, Castle & Key Distillery, Bourbon Barrel Foods, ShopCaterpillar and American Beverage Marketers. Since 2023, RedTag’s work has received two Emmy Awards and more than 35 ADDY and AIGA awards. The agency is a four-time Louisville Business First Fast 50 honoree and was named one of the 2026 Best Places to Work in Kentucky.

To learn more about its outcome-based programs, visit RedTag Programs

About RedTag

RedTag is an independent, strategy-first marketing agency based in Louisville, Kentucky. Established in 2008, the agency starts every engagement by understanding the goal before recommending tactics. With a foundation rooted in discovery, RedTag delivers full-scale marketing campaigns built around each client’s business goals. RedTag serves organizations across hospitality, sports, agriculture, government, retail and consumer packaged goods. Learn more at redtag.agency.

View original content to download multimedia:https://www.prnewswire.com/news-releases/as-ai-speeds-up-marketing-louisvilles-redtag-bets-on-strategy-302911869.html

SOURCE RED TAG LLC

Continue Reading

Trending